As biosimilars become a 'hot topic' in the rare disease world, the IGA started to educate its members about them two years ago with a presentation from Prof Dingermann on what biosimilars are at our biennial members meeting in Riga, 2018. We continued to share more information on biosimilars in our newsletters.
Still, confusion exists among several physicians and patients around the world and the term 'biosimilar' is not consistenly used; the same term 'biosimilar' carries different meanings in different countries. This is especially true in less regulated countries. However, clear definition and guidelines were developed in regions with high regulatory vigilance, such as the European Union, the USA, Japan, Canada and Australia.
In these countries, no biosimilars for Gaucher disease have been approved so far.
The IGA was a co-author of a scientific paper titled 'The road to biosimilars in rare diseases – ongoing lessons from Gaucher disease', published in March 2020 Issue of American Journal of Hematology and we encourage you to read it and share it with your doctors and patients, especially those of you who have encounted the following medicines: Abcertin, Asbroder and Glurazyme.
You can read the published article here